| 1.54 -0.04 (-2.53%) | 06-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.32 | 1-year : | 2.71 |
| Resists | First : | 1.99 | Second : | 2.32 |
| Pivot price | 1.55  |
|||
| Supports | First : | 1.14 | Second : | 0.62 |
| MAs | MA(5) : | 1.55 |
MA(20) : | 1.32 |
| MA(100) : | 0.93 |
MA(250) : | 1.61 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 66.9 |
D(3) : | 68.2 |
| RSI | RSI(14): 64.1 |
|||
| 52-week | High : | 5.5 | Low : | 0.57 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ INM ] has closed above bottom band by 45.1%. Bollinger Bands are 137.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.58 - 1.59 | 1.59 - 1.6 |
| Low: | 1.46 - 1.47 | 1.47 - 1.48 |
| Close: | 1.49 - 1.51 | 1.51 - 1.52 |
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
Fri, 05 Jun 2026
ADAR1/Manager Daniel Schneeberger reports 24.1% stake in InMed (NASDAQ: INM) - Stock Titan
Thu, 04 Jun 2026
InMed Pharmaceuticals regains Nasdaq compliance - Investing.com
Thu, 04 Jun 2026
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements - TMX Newsfile
Wed, 03 Jun 2026
Squadron Capital Management LLC Acquires 325,000 Shares in InMed Pharmaceuticals Inc - GuruFocus
Wed, 20 May 2026
/C O R R E C T I O N -- InMed Pharmaceuticals/ - PR Newswire
Tue, 19 May 2026
InMed Pharmaceuticals Amends Preferred Investment Options - TMX Newsfile
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 21.8 (%) |
| Shares Short | 27 (K) |
| Shares Short P.Month | 96 (K) |
| EPS | -1.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.42 |
| Profit Margin | -172.2 % |
| Operating Margin | -162.8 % |
| Return on Assets (ttm) | -54.7 % |
| Return on Equity (ttm) | -112.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.51 |
| Sales Per Share | 1.49 |
| EBITDA (p.s.) | -2.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.44 |
| Price to Sales | 1 |
| Price to Cash Flow | -0.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|